• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Eleven science stories likely to make big news in 2023
As the COVID-19 pandemic enters its fourth year as a global health emergency, researchers will continue pushing to help make the disease manageable and ordinary. They will track hundreds of subvariants of Omicron, the highly transmissible but seemingly less lethal strain of SARSCoV-2 that dominated in 2022. Virologists will watch the virus’ evolution this year to see whether it has finally slowed or a more dangerous variant pops up, evading much of the immunity that humanity has built up to previous ones. Vaccine researchers hope to develop new shots that provide broad protection against a variety of coronaviruses.  Ano...
Source: ScienceNOW - January 4, 2023 Category: Science Source Type: news

News at a glance: New gene therapy, Europe ’s drought, and a black hole’s photon ring
ARCHAEOLOGY Drought exposes ‘Spanish Stonehenge’ for study Scientists are rushing to examine a 7000-year-old stone circle in central Spain that had been drowned by a reservoir for decades and was uncovered after the drought plaguing Europe lowered water levels. Nicknamed the “Spanish Stonehenge”—although 2000 years older than the U.K. stone circle—the Dolmen of Guadalperal (above) was described by archaeologists in the 1920s. The approximately 100 standing stones, up to 1.8 meters tall and arranged around an oval open space, were submerged in the Valdecañas reservoir after the construction of a ...
Source: Science of Aging Knowledge Environment - August 25, 2022 Category: Geriatrics Source Type: research

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv. “Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help prot...
Source: Johnson and Johnson - July 1, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

What We Learned About Genetic Sequencing During COVID-19 Could Revolutionize Public Health
You don’t want to be a virus in Dr. David Ho’s lab. Pretty much every day since the COVID-19 pandemic began, Ho and his team have done nothing but find ways to stress SARS-CoV-2, the virus that causes the disease. His goal: pressure the virus relentlessly enough that it mutates to survive, so drug developers can understand how the virus might respond to new treatments. As a virologist with decades of experience learning about another obstinate virus, HIV, Ho knows just how to apply that mutation-generating stress, whether by starving the virus, bathing it in antibodies that disrupt its ability to infect cells, ...
Source: TIME: Health - June 11, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 feature Genetics Magazine Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants ...
Source: Johnson and Johnson - April 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents
New Brunswick, NJ (April 2, 2021) – Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. “The COVID-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “It is vital that we develop vaccines for everyone, everywher...
Source: Johnson and Johnson - April 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this management. ...
Source: JEMS Patient Care - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

J & J ’s COVID-19 Vaccine Will Enter Phase 3 Testing, the Fourth To Reach That Stage
Johnson & Johnson announced today (Sept. 23) that it is launching a large-scale Phase 3 test of its COVID-19 vaccine candidate, which was developed based on science supported by the National Institutes of Health. The vaccine, being tested through the company’s Janssen Pharmaceuticals arm, will be the fourth to enter late stage studies, following candidates from Moderna, Pfizer-BioNTech and AstraZeneca. Unlike those vaccine candidates, which all require two shots, J&J’s vaccine involves a single injection. That means it could require half the number of doses to immunize the same number of people. J&J...
Source: TIME: Health - September 23, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Pages: 1  2